Literature DB >> 10587770

Valsartan. Just a second-line antihypertensive drug.

.   

Abstract

Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. At a dose of 40 mg/d, its antihypertensive effect is inconsistent. At 80 mg/d its effect on blood pressure, its adverse effects, and its contraindications (mainly pregnancy and renal artery stenosis) are similar to those of angiotensin-converting enzyme (ACE) inhibitors, except that coughing is rarer with valsartan than with ACE inhibitors. Valsartan has no demonstrated advantage over losartan, another angiotensin II antagonist. Valsartan has not been shown to prevent complications of arterial hypertension, and its use is, therefore, less well validated than that of diuretics and beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10587770      PMCID: PMC2328654     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  9 in total

Review 1.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.

Authors:  A Markham; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.

Authors:  S Oparil; S Dyke; F Harris; J Kief; D James; A Hester; S Fitzsimmons
Journal:  Clin Ther       Date:  1996 Sep-Oct       Impact factor: 3.393

3.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.

Authors:  G Hegner; G Faust; F Freytag; S Meilenbrock; J Sullivan; F Bodin
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.

Authors:  J Benz; C Oshrain; D Henry; C Avery; Y T Chiang; M Gatlin
Journal:  J Clin Pharmacol       Date:  1997-02       Impact factor: 3.126

5.  Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.

Authors:  A D Bremner; M Baur; P Oddou-Stock; F Bodin
Journal:  Clin Exp Hypertens       Date:  1997-11       Impact factor: 1.749

6.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.

Authors:  N J Holwerda; R Fogari; P Angeli; C Porcellati; C Hereng; P Oddou-Stock; R Heath; F Bodin
Journal:  J Hypertens       Date:  1996-09       Impact factor: 4.844

7.  Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension.

Authors:  A Fortuño; J Tisaire; R López; J Bueno; J Díez
Journal:  Am J Hypertens       Date:  1997-01       Impact factor: 2.689

8.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Authors:  B Pitt; R Segal; F A Martinez; G Meurers; A J Cowley; I Thomas; P C Deedwania; D E Ney; D B Snavely; P I Chang
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

9.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.

Authors:  L Corea; O Cardoni; R Fogari; P Innocenti; C Porcellati; M Provvidenza; S Meilenbrock; J Sullivan; F Bodin
Journal:  Clin Pharmacol Ther       Date:  1996-09       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.